ArticleCureus2025
Rare Case of Pulmonary Perivascular Epithelioid Cell Tumor (PEComa) Causing Right Lung Collapse Managed With Bronchial Stenting: A Clinical Challenge.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary perivascular epithelioid cell tumor (PEComa) is an extremely uncommon mesenchymal tumor; pulmonary PEComas can present serious difficulties for both diagnosis and treatment. We present the case of a 62-year-old male with a history of unresectable PEComa of the upper back with metastatic progression to the lungs. Despite ongoing sirolimus therapy, the patient experienced significant tumor growth, presenting to the emergency department with respiratory distress, and was found to have a rapidly enlarging pulmonary mass, later referred for bronchial stenting for palliative treatment. Due to the rarity of these tumors, diagnosis often requires a high index of suspicion and relies on histopathologic confirmation, including immunohistochemistry for melanocytic and muscle markers. Imaging alone is insufficient to distinguish PEComas from other pulmonary masses, underscoring the need for tissue diagnosis. Furthermore, the clinical behaviour of pulmonary PEComas is unpredictable; some remain indolent, while others exhibit aggressive metastatic potential. This heterogeneity complicates treatment planning and highlights the need for individualized, multidisciplinary approaches. We highlight the fact that pulmonary PEComa can rapidly progress and can cause significant morbidity. Palliation with bronchial stenting can be a reasonable option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.